Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatofibrosarcoma Protuberans

NCT07646080 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Dermatofibrosarcoma Protuberans (DFSP)

Interventions

DRUG: Toripalimab
DRUG: Anlotinib
DRUG: Standard Chemotherapy

Sponsor

Yanjie Zhang, MD